<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347845">
  <stage>Registered</stage>
  <submitdate>12/12/2011</submitdate>
  <approvaldate>15/12/2011</approvaldate>
  <actrnumber>ACTRN12611001287921</actrnumber>
  <trial_identification>
    <studytitle>A pilot study of the impact of high-dose vitamin D supplementation on non-alcoholic steatohepatitis</studytitle>
    <scientifictitle>A pilot study of the impact of high-dose vitamin D supplementation on non-alcoholic steatohepatitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non-alcoholic steatohepatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>High-dose oral vitamin D3 (cholecalciferol) in a once weekly dosing form for 24 weeks, initially at 25,000 IU/week, targeting a 25(OH)D level of 100-125 nmol/L. The dose will be titrated upwards or downwards if necessary every 6 weeks, depending on the 25(OH)D level on blood testing performed every 6 weeks.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>2 or more point improvement in NAFLD Activity Score with no worsening of fibrosis on follow up liver biopsy</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Resolution of steatohepatitis on follow up liver biopsy</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in steatohepatitis as measured by Brunt score on follow up liver biopsy</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement, on follow up liver biopsy, of individual components of the NAFLD Activity Score: steatosis, lobular inflammation, hepatocyte ballooning,</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety, as defined by lack of adverse events (such as hypercalcaemia) and serious adverse events (such as nephrolithiasis, complication of percutaneous liver biopsy).</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in ALT (a liver function test assessing inflammatory activity in the liver) and HOMA-IR score (a measure of insulin resistance on blood testing)</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in fibrosis stage on follow up liver biopsy</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>NAFLD Activity Score of 4 or more, with a score of at least 1 point each in steatosis, lobular inflammation and hepatocyte ballooning component scores, on liver biopsy within the previous 3 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Alcohol intake of 30g/day or greater in males and 20g/day or greater in females
Any contraindication to percutaneous liver biopsy
Presence of HBsAg+ or HCV PCR+, or any other cause of liver disease other than NASH
Pregnant or breast-feeding
Uncontrolled Type 2 Diabetes Mellitus
Inability to provide informed consent
Cirrhosis
Presence of significant cardiovascular or renal disease
Corrected calcium &gt;2.60 mmol/L
History of nephrolithiasis or sarcoidosis
Current therapy with vitamin D, vitamin E, thiazolidinediones, milk thistle, hepatic enzyme inhibitors or with drugs known to cause steatohepatitis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>16/12/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Matthew Kitson</primarysponsorname>
    <primarysponsoraddress>Department of Gastroenterology
Alfred Hospital
55 Commercial Rd
Melbourne 
VIC 3004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Alfred Hospital</fundingname>
      <fundingaddress>55 Commercial Rd
Melbourne
VIC 3004</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Currently there is no treatment for the common liver condition NASH. Vitamin D has effects which can act against inflammation and scarring in the liver, which are important in the development of NASH. This study will assess high-dose vitamin D as a treatment for NASH.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital HREC</ethicname>
      <ethicaddress>55 Commercial Rd
Melbourne 
VIC 3004</ethicaddress>
      <ethicapprovaldate>28/06/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Matthew Kitson</name>
      <address>Gastroenterology Department
Alfred Hospital
55 Commercial Rd
Melbourne VIC 3004</address>
      <phone>+61 3 90762223</phone>
      <fax />
      <email>m.kitson@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Matthew Kitson</name>
      <address>Gastroenterology Department
Alfred Hospital
55 Commercial Rd
Melbourne VIC 3004</address>
      <phone>+61 3 90762223</phone>
      <fax />
      <email>m.kitson@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>